About

early phase clinical research support

Funds are available to support early phase clinical trials initiated by Consortium investigators* through the Early Phase Clinical Research Support (EPCRS) mechanism of the Cancer Center Support Grant (CCSG).  These funds are intended to support early phase clinical trials that will provide data that can be used as the basis for larger, later phase trials that are funded via competitive grant applications and industry.  Priority will be given to highly innovative, proof-of-principle studies with the potential to lead to future trials.

*Consortium investigators are members of the FHCRC/UW Cancer Consortium on or by the application due date.

Eligibility

In order to apply for EPCRS, the study must meet the following criteria:

  • Phase I, pre-Phase I or pilot study
  • Support initial early phase testing of an agent or device for the diagnosis, prevention, detection or treatment of cancer
  • Conceptualized/designed by a Consortium member
  • Typically less than one year in duration
  • Does not receive funding through other peer reviewed research grants, cooperative agreements or contracts
  • May receive partial support from industry
  • Approved by the Scientific Review Committee (SRC), though investigators may submit applications prior to SRC approval (see below)

How Funds Can be Used

Funding in these pilot and phase I clinical studies is limited to support of:

  • Nurses and data managers for a pilot (pre-phase I) or phase I clinical trial,
  • Costs associated with generation of preliminary data through other early phase clinically related activities, for example:
    • Purchase of imaging time for scans related to early phase clinical research
    • Support for IND or IDE applications
    • Pharmacodynamic studies, e.g., use of sequential or pre- and post- biopsies or assays of activity in peripheral tissues to identify investigational agents deserving full clinical development, clinical evaluation of structurally similar analogues directed at the same molecular target, determination of a dosing regimen for an agent to be used in combination therapy, or development of novel imaging probes that establish mechanism of action in patient samples or provide functional and metabolic information about the effect of a drug on its target.

Funds may not be used for any supervisory functions.

How to Apply

An RFA will be released in spring, 2014.

Menu Search